Table 1. Patient demographics and clinical information versus EGFR mutation status.
| Clinical variables | No of patients (%) | EGFR mutation status by SMART assay | Significance (P value) | |
|---|---|---|---|---|
| Mutation positive | Mutation negative | |||
| Age | ||||
| ≤ 65 | 116 (63.0%) | 52 | 64 | 0.2325 (> 0.05) |
| >65 | 68 (37.0%) | 28 | 40 | |
| Gender | ||||
| Male | 109 (59.2%) | 37 | 72 | 0.0017 (< 0.05) |
| Female | 75 (40.8%) | 43 | 32 | |
| Smoking history | ||||
| Never | 85 (46.2%) | 49 | 36 | 0.0003 (< 0.05) |
| Ever | 99 (53.8%) | 31 | 68 | |
| Histology # | ||||
| Adenocarcinoma | 156 (86.7%) | 74 | 82 | 0.094 (> 0.05) |
| Squamous carcinoma | 24 (13.3%) | 7 | 17 | |
| Stage of NSCLC | ||||
| Early (I+II) | 89 (48.4%) | 37 | 52 | 0.6138 (> 0.05) |
| Late (III+IV) | 95 (51.6%) | 43 | 52 | |
#
The two tumours with mucoepidermoid carcinoma and two with neuroendocrine carcinoma were excluded from the analysis